logo
You can actually die of a broken heart after bereavement, study shows

You can actually die of a broken heart after bereavement, study shows

CNN5 days ago
You can actually die of a broken heart after the death of a loved one, especially if the grief is overwhelming, new research shows.
Bereaved relatives who experienced 'high levels' of grief symptoms were more likely to die in the 10 years following their bereavement than those who experienced 'low levels' of grief, a study published Friday in the journal Frontiers in Public Health found.
In the study, coauthor Mette Kjærgaard Nielsen, a postdoctoral researcher at Aarhus University in Denmark, and her colleagues investigated the long-term health outcomes of bereaved relatives in Denmark over the course of 10 years, dividing the 1,735 participants into groups who experienced 'low levels' and 'high levels' of grief symptoms.
During the study period, 26.5% of the relatives who showed high levels of grief died, compared with 7.3% of those who were less powerfully affected.
These 'high levels' of grief are defined as someone experiencing more than half of nine grief symptoms researchers have identified. These include feeling emotionally numb or that life is meaningless; experiencing difficulty accepting the loss; and experiencing confusion over their own identity.
Participants were asked to fill in questionnaires when they first enrolled in the study, as well as six months and three years after their bereavement, allowing researchers to collect their symptoms.
At the same time, researchers observed how often the study participants interacted with the health care system, finding that relatives with high grief symptoms also used more antidepressant medication, mental health services and primary care services.
'Those with a high grief trajectory seem to be a vulnerable group of relatives already before the death, with need for special attention,' Nielsen told CNN via email.
'(They) may need additional support. They may experience distress and have difficulties coping with the situation,' she said, pointing to previous studies that have highlighted low socioeconomic status, poor self-reported health, and higher symptoms of depression and anxiety as all contributing to overwhelming grief.
Even accounting for these risk factors, the researchers have 'done a good job' isolating the specific effect of grief, Sian Harding, a cardiologist and professor emeritus of cardiac pharmacology at Imperial College London who wasn't involved in the research, told CNN.
One of the 'key things' about the paper is its longitudinal perspective, she said, since 'we know very well that there's an acute effect of any kind of bereavement on heart health.'
'It was not a particular surprise to me that this particular form of stress, while prolonged, has a damaging effect on the body. It can come out particularly as heart disease, but other things as well,' Harding added.
While this study didn't investigate the bereaved relatives' causes of death, it aligns with wider research showing the effect a traumatic loss can have on a person's physical health.
One cardiac condition known as broken heart syndrome — also called stress-induced cardiomyopathy or Takotsubo cardiomyopathy — is a well-established acute phenomenon, triggered by intensely stressful situations, like losing a loved one.
Prolonged stress caused by bereavement can also cause raised blood pressure, raised cortisol, an increased risk of diabetes, and poor mental health, Harding said. She also noted previous research into broken heart syndrome that found that some people die on the anniversary of their bereavement.
Findings from the latest study suggest that healthcare workers 'may be able to discover distressed relatives early in the patient's illness trajectory and offer follow up,' Nielsen said.
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10

Yahoo

timean hour ago

  • Yahoo

H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10

Atai Life Sciences (NASDAQ:ATAI) is one of the best biotech penny stocks to buy right now. On July 30, H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Atai Life Sciences (NASDAQ:ATAI) to $15 from $10 while keeping a Buy rating on the shares. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The firm told investors that it is bullish on Atai Life Sciences (NASDAQ:ATAI) despite the Phase 2b trial, which evaluated indiabine in patients with cognitive impairment associated with schizophrenia, missing the primary endpoint. The analyst added in a research note that management reiterated Atai Life Sciences' (NASDAQ:ATAI) focus on its wholly-owned psychedelics pipeline in a follow-up call. This includes BPL-003, which has continued to surpass expectations. The firm thus cited Atai Life Sciences' (NASDAQ:ATAI) focus on its 'most promising near-term asset' for the target upgrade. Headquartered in Germany, Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on treating mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts
Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts

Yahoo

time2 hours ago

  • Yahoo

Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts

A week ago, Siemens Healthineers AG (ETR:SHL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 2.0% to hit €5.7b. Siemens Healthineers reported statutory earnings per share (EPS) €0.49, which was a notable 17% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 18 analysts covering Siemens Healthineers are now predicting revenues of €24.6b in 2026. If met, this would reflect a modest 5.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 17% to €2.29. In the lead-up to this report, the analysts had been modelling revenues of €24.8b and earnings per share (EPS) of €2.34 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. See our latest analysis for Siemens Healthineers The consensus price target held steady at €59.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Siemens Healthineers, with the most bullish analyst valuing it at €65.00 and the most bearish at €50.00 per share. This is a very narrow spread of estimates, implying either that Siemens Healthineers is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Siemens Healthineers' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Siemens Healthineers. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Siemens Healthineers. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Siemens Healthineers going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts
Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts

Yahoo

time2 hours ago

  • Yahoo

Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts

A week ago, Siemens Healthineers AG (ETR:SHL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 2.0% to hit €5.7b. Siemens Healthineers reported statutory earnings per share (EPS) €0.49, which was a notable 17% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 18 analysts covering Siemens Healthineers are now predicting revenues of €24.6b in 2026. If met, this would reflect a modest 5.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 17% to €2.29. In the lead-up to this report, the analysts had been modelling revenues of €24.8b and earnings per share (EPS) of €2.34 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. See our latest analysis for Siemens Healthineers The consensus price target held steady at €59.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Siemens Healthineers, with the most bullish analyst valuing it at €65.00 and the most bearish at €50.00 per share. This is a very narrow spread of estimates, implying either that Siemens Healthineers is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Siemens Healthineers' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Siemens Healthineers. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Siemens Healthineers. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Siemens Healthineers going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store